Figure 3. New approach using immune context classification of tumors to guide anticancer therapy and increase the response to immune checkpoint inhibitors.

ADORA2A, A_2a adenosine receptor; CSF1R, colony-stimulating factor 1 receptor; DDR, DNA damage response; HDAC, histone deacetylase; IDO, indoleamine 2,3-dioxygenase; LIGHT, tumor necrosis factor superfamily member 14; STING, stimulator of IFN genes.